✦ LIBER ✦

Fecal calprotectin is useful in predicting disease relapse in pediatric inflammatory bowel disease

✍ Scribed by Dorota Walkiewicz; Steven L. Werlin; Daryl Fish; Mathew Scanlon; Patrick Hanaway; Subra Kugathasan

Publisher: John Wiley and Sons
Year: 2008
Tongue: English
Weight: 119 KB
Volume: 14
Category: Article
ISSN: 1078-0998
DOI: 10.1002/ibd.20376

No coin nor oath required. For personal study only.

✦ Synopsis

Background: Fecal calprotectin (FC) has been proposed as a noninvasive surrogate marker to determine the degree of intestinal inflammation and predicting relapse in patients with inflammatory bowel disease (IBD). The aim was to compare FC levels in IBD and healthy controls, to correlate FC levels with clinical disease activity, and to assess whether FC levels can be used to predict clinical relapse in children with IBD.

Methods: Enzyme-linked immunosorbent assay (ELISA) determined levels of FC were measured in more than 1 stool samples (n) from 32 IBD patients (n ϭ 97) and from 34 healthy controls (n ϭ 37). Disease activity was assessed by the Harvey-Bradshaw index in Crohn's disease (CD) and by Physician's Global Assessment (PGA) in both CD and ulcerative colitis (UC). Clinical events were recorded up to 9 months following stool collection in CD patients. Wilcoxon rank sum test and Fisher's exact tests were used to compare FC levels in IBD patients and in control. Kaplan-Meyer analysis was used to determine a risk of clinical relapse in relation to FC levels.

Results:

The IBD group had higher FC levels (range 17-7500 g/g) compared with control (16 -750 g/g, P Ͻ 0.0001). FC levels were higher during relapse (CD, 3214 Ϯ 2186; UC, 2819 Ϯ 1610) compared to remission (CD, 1373 Ϯ 1630; UC, 764 Ϯ 869; P Ͻ 0.0001). Among those with clinical relapse, 90% had FC levels more than 400 g/g in CD. Eighty-nine percent of CD encounters with FC levels less than 400 g/g remained in clinical remission.

Conclusions: FC levels differentiate active IBD from controls.

Among children with CD and in remission, FC levels may be useful in predicting impending clinical relapse.

📜 SIMILAR VOLUMES

Fecal calprotectin and lactoferrin for t

Fecal calprotectin and lactoferrin for the prediction of inflammatory bowel disease relapse

✍ Javier P. Gisbert; Fernando Bermejo; Jose-Lázaro Pérez-Calle; Carlos Taxonera; I 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 181 KB

## Background: The purpose of the study was to determine the role of fecal calprotectin and lactoferrin in the prediction of inflammatory bowel disease relapses, both in patients with ulcerative colitis (uc) and crohn's disease (cd), in a large, long-term, follow-up study. ## Methods: The prospec

Fecal calprotectin complements routine l

Fecal calprotectin complements routine laboratory investigations in diagnosing childhood inflammatory bowel disease

✍ Michael A. Quail; Richard K. Russell; Johan E. Van Limbergen; Pam Rogers; Hazel 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 127 KB

## Background: We aimed to study fecal calprotectin in Scottish children with inflammatory bowel disease (IBD) and compare its diagnostic accuracy with blood parameters. ## Methods: Stool samples from 48 Scottish children (29 males, 19 females) had calprotectin measured at IBD diagnosis. The me

Fecal S100A12 and fecal calprotectin as

Fecal S100A12 and fecal calprotectin as noninvasive markers for inflammatory bowel disease in children

✍ Marc A. Sidler; Steven T. Leach; Andrew S. Day 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 123 KB

## Background: Fecal calprotectin is a sensitive marker for gut inflammation. recently, we have established that a related protein, s100a12, is elevated in the feces of children with inflammatory bowel disease (ibd). this may represent a specific and sensitive disease marker. the objective was to i

Clinical role of calprotectin assay in d

Clinical role of calprotectin assay in determining histological relapses in children affected by inflammatory bowel diseases

✍ A. Diamanti; F. Colistro; M. S. Basso; B. Papadatou; P. Francalanci; F. Bracci; 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 126 KB 👁 2 views

Background: Inflammatory bowel diseases (IBD) are characterized by periods of remission with recurrent episodes of symptom exacerbation because of acute intestinal inflammation, which is correctly evaluated by endoscopy with biopsy sampling. However, many surrogate markers of intestinal inflammation

Thromboembolism in pediatric inflammator

Thromboembolism in pediatric inflammatory bowel disease: Systematic review

✍ Marzia Lazzerini; Matteo Bramuzzo; Massimo Maschio; Stefano Martelossi; Alessand 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 191 KB 👁 1 views

Background: Several studies suggest an increased risk of venous and arterial thromboembolism (TE) in adults with inflammatory bowel disease (IBD) compared to the general population. We performed a systematic review of studies on incidence and characteristic of TE in children with IBD. Methods: We s

Nutritional concerns in pediatric inflam

Nutritional concerns in pediatric inflammatory bowel disease patients

✍ Michael D. Kappelman; Athos Bousvaros 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 190 KB

## Abstract In approximately one‐fourth of patients with Crohn's disease (CD) and ulcerative colitis (UC), disease onset occurs during childhood and adolescence. In addition to gastrointestinal and extraintestinal symptoms of inflammatory bowel disease (IBD), children with these conditions often ex